Literature DB >> 19949399

Telavancin.

G Ralph Corey, Martin E Stryjewski, Wim Weyenberg, Uma Yasothan, Peter Kirkpatrick.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19949399     DOI： 10.1038/nrd3051

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  12 in total

1.  Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424).

Authors:  Michael R Leadbetter; Stacy M Adams; Bettina Bazzini; Paul R Fatheree; Dane E Karr; Kevin M Krause; Bernice M T Lam; Martin S Linsell; Matthew B Nodwell; John L Pace; Kelly Quast; Jeng-Pyng Shaw; Elizabeth Soriano; Sean G Trapp; Jenny D Villena; Terry X Wu; Burton G Christensen; J Kevin Judice
Journal:  J Antibiot (Tokyo)       Date:  2004-05       Impact factor: 2.649

2.  Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Authors:  Deborah L Higgins; Ray Chang; Dmitri V Debabov; Joey Leung; Terry Wu; Kevin M Krause; Erik Sandvik; Jeffrey M Hubbard; Koné Kaniga; Donald E Schmidt; Qiufeng Gao; Robert T Cass; Dane E Karr; Bret M Benton; Patrick P Humphrey
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Tissue penetration of telavancin after intravenous administration in healthy subjects.

Authors:  Heather K Sun; Kenneth Duchin; Charles H Nightingale; Jeng-Pyng Shaw; Julie Seroogy; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm?

Authors:  Fred C Tenover
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

5.  Methicillin-resistant S. aureus infections among patients in the emergency department.

Authors:  Gregory J Moran; Anusha Krishnadasan; Rachel J Gorwitz; Gregory E Fosheim; Linda K McDougal; Roberta B Carey; David A Talan
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

Review 6.  Glycopeptides in clinical development: pharmacological profile and clinical perspectives.

Authors:  Françoise Van Bambeke
Journal:  Curr Opin Pharmacol       Date:  2004-10       Impact factor: 5.547

7.  Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.

Authors:  Sharath S Hegde; Noe Reyes; Tania Wiens; Nicole Vanasse; Robert Skinner; Julia McCullough; Koné Kaniga; John Pace; Roger Thomas; Jeng-Pyng Shaw; Glen Obedencio; J Kevin Judice
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  In vitro activity of telavancin against resistant gram-positive bacteria.

Authors:  Kevin M Krause; Marika Renelli; Stacey Difuntorum; Terry X Wu; Dmitri V Debabov; Bret M Benton
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

9.  Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.

Authors:  Martin E Stryjewski; Donald R Graham; Samuel E Wilson; William O'Riordan; David Young; Arnold Lentnek; Douglas P Ross; Vance G Fowler; Alan Hopkins; H David Friedland; Steven L Barriere; Michael M Kitt; G Ralph Corey
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

10.  Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.

Authors:  Christopher S Lunde; Stephanie R Hartouni; James W Janc; Mathai Mammen; Patrick P Humphrey; Bret M Benton
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191
View more
  20 in total

1.  Vancomycin C-Terminus Guanidine Modifications and Further Insights into an Added Mechanism of Action Imparted by a Peripheral Structural Modification.

Authors:  Zhi-Chen Wu; Michael D Cameron; Dale L Boger
Journal:  ACS Infect Dis       Date:  2020-07-14       Impact factor: 5.084

2.  Metabolism of small antimicrobial β(2,2)-amino acid derivatives by murine liver microsomes.

Authors:  Terkel Hansen; Morten K Moe; Trude Anderssen; Morten B Strøm
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-03-01       Impact factor: 2.441

3.  Case report: artificial elevation of prothrombin time by telavancin.

Authors:  Derek F Amanatullah; Matthew J Lopez; Robert C Gosselin; Munish C Gupta
Journal:  Clin Orthop Relat Res       Date:  2012-11-06       Impact factor: 4.176

4.  N-Terminus Alkylation of Vancomycin: Ligand Binding Affinity, Antimicrobial Activity, and Site-Specific Nature of Quaternary Trimethylammonium Salt Modification.

Authors:  Zhi-Chen Wu; Nicholas A Isley; Dale L Boger
Journal:  ACS Infect Dis       Date:  2018-08-08       Impact factor: 5.084

5.  Total syntheses and initial evaluation of [Ψ[C(═S)NH]Tpg⁴]vancomycin, [Ψ[C(═NH)NH]Tpg⁴]vancomycin, [Ψ[CH₂NH]Tpg⁴]vancomycin, and their (4-chlorobiphenyl)methyl derivatives: synergistic binding pocket and peripheral modifications for the glycopeptide antibiotics.

Authors:  Akinori Okano; Atsushi Nakayama; Kejia Wu; Erick A Lindsey; Alex W Schammel; Yiqing Feng; Karen C Collins; Dale L Boger
Journal:  J Am Chem Soc       Date:  2015-03-09       Impact factor: 15.419

Review 6.  A brief history of antibiotics and select advances in their synthesis.

Authors:  Kyriacos C Nicolaou; Stephan Rigol
Journal:  J Antibiot (Tokyo)       Date:  2017-07-05       Impact factor: 2.649

Review 7.  Biological, chemical, and biochemical strategies for modifying glycopeptide antibiotics.

Authors:  Edward Marschall; Max J Cryle; Julien Tailhades
Journal:  J Biol Chem       Date:  2019-10-31       Impact factor: 5.157

8.  Membrane-Targeting DCAP Analogues with Broad-Spectrum Antibiotic Activity against Pathogenic Bacteria.

Authors:  Katherine A Hurley; Victoria A Heinrich; Jeremy R Hershfield; Samandra T Demons; Douglas B Weibel
Journal:  ACS Med Chem Lett       Date:  2015-03-01       Impact factor: 4.345

Review 9.  Total Syntheses of Vancomycin-Related Glycopeptide Antibiotics and Key Analogues.

Authors:  Akinori Okano; Nicholas A Isley; Dale L Boger
Journal:  Chem Rev       Date:  2017-04-24       Impact factor: 60.622

Review 10.  The evolving role of chemical synthesis in antibacterial drug discovery.

Authors:  Peter M Wright; Ian B Seiple; Andrew G Myers
Journal:  Angew Chem Int Ed Engl       Date:  2014-07-02       Impact factor: 15.336
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.